cyproconazole has been researched along with Fatty Liver in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Braeuning, A; de Sousa, G; Durinck, S; Katsanou, ES; Konstantinidou, P; Lampen, A; Luckert, C; Machera, K; Milani, ES; Peijnenburg, AACM; Rahmani, R; Rajkovic, A; Rijkers, D; Spyropoulou, A; Stamou, M; Stoopen, G; Sturla, S; Wollscheid, B; Zucchini-Pascal, N | 1 |
| Currie, RA; Milburn, G; Moggs, JG; Pastoor, T; Peffer, RC; Rusyn, I; Waechter, F; Wright, J | 1 |
2 other study(ies) available for cyproconazole and Fatty Liver
| Article | Year |
|---|---|
Adverse Outcome Pathway-Driven Analysis of Liver Steatosis in Vitro: A Case Study with Cyproconazole.
Topics: Adverse Outcome Pathways; Biological Assay; Cell Line, Tumor; Dose-Response Relationship, Drug; Fatty Liver; Fungicides, Industrial; Gene Expression; HEK293 Cells; Hepatocytes; Humans; Mitochondria, Liver; Models, Biological; Polymerase Chain Reaction; Receptors, Cytoplasmic and Nuclear; Risk Assessment; Triazoles; Triglycerides | 2018 |
Mouse liver effects of cyproconazole, a triazole fungicide: role of the constitutive androstane receptor.
Topics: Administration, Oral; Animals; Antigens, Differentiation; Aryl Hydrocarbon Hydroxylases; Cell Proliferation; Cytochrome P450 Family 2; Diet; Dose-Response Relationship, Drug; Enzyme Induction; Fatty Liver; Fungicides, Industrial; Gene Expression Regulation; Gene Silencing; Hepatocytes; Hypertrophy; Liver; Male; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Knockout; Organ Size; Phenobarbital; Proto-Oncogene Proteins c-mdm2; Receptors, Androgen; Species Specificity; Steroid Hydroxylases; Triazoles; Vacuoles | 2007 |